Halozyme Therapeutics Stock Probability of Future Stock Price Finishing Under 48.29
| HALO Stock | USD 48.47 0.68 1.42% |
Halozyme |
Halozyme Therapeutics Target Price Odds to finish below 48.29
The tendency of Halozyme Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 48.29 or more in 90 days |
| 48.47 | 90 days | 48.29 | about 9.06 |
Based on a normal probability distribution, the odds of Halozyme Therapeutics to drop to $ 48.29 or more in 90 days from now is about 9.06 (This Halozyme Therapeutics probability density function shows the probability of Halozyme Stock to fall within a particular range of prices over 90 days) . Probability of Halozyme Therapeutics price to stay between $ 48.29 and its current price of $48.47 at the end of the 90-day period is near 1 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.51 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Halozyme Therapeutics will likely underperform. Additionally Halozyme Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Halozyme Therapeutics Price Density |
| Price |
Predictive Modules for Halozyme Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Halozyme Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Halozyme Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Halozyme Therapeutics is not an exception. The market had few large corrections towards the Halozyme Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Halozyme Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Halozyme Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.51 | |
β | Beta against Dow Jones | 1.51 | |
σ | Overall volatility | 5.52 | |
Ir | Information ratio | -0.12 |
Halozyme Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Halozyme Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Halozyme Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Halozyme Therapeutics generated a negative expected return over the last 90 days | |
| Halozyme Therapeutics has high historical volatility and very poor performance | |
| Halozyme Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: HALO Withdraws Acquisition Bid for EVO, Reaffirms 24 View, Stock Up |
Halozyme Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Halozyme Stock often depends not only on the future outlook of the current and potential Halozyme Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Halozyme Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 134.2 M | |
| Cash And Short Term Investments | 336 M |
Halozyme Therapeutics Technical Analysis
Halozyme Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Halozyme Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Halozyme Therapeutics. In general, you should focus on analyzing Halozyme Stock price patterns and their correlations with different microeconomic environments and drivers.
Halozyme Therapeutics Predictive Forecast Models
Halozyme Therapeutics' time-series forecasting models is one of many Halozyme Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Halozyme Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Halozyme Therapeutics
Checking the ongoing alerts about Halozyme Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Halozyme Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Halozyme Therapeutics generated a negative expected return over the last 90 days | |
| Halozyme Therapeutics has high historical volatility and very poor performance | |
| Halozyme Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: HALO Withdraws Acquisition Bid for EVO, Reaffirms 24 View, Stock Up |
Check out Halozyme Therapeutics Backtesting, Halozyme Therapeutics Valuation, Halozyme Therapeutics Correlation, Halozyme Therapeutics Hype Analysis, Halozyme Therapeutics Volatility, Halozyme Therapeutics History as well as Halozyme Therapeutics Performance. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.721 | Earnings Share 3.06 | Revenue Per Share 7.431 | Quarterly Revenue Growth 0.343 | Return On Assets 0.1487 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.